Human IL29 / IFN lambda ELISA Kit

Arigo Biolaboratories

Human IL29 / IFN lambda ELISA Kit

23

ELISA

CV:

15 pg/ml

No significant cross-reactivity or interference with Human IFN-alphaA/D, IFN-alphaA, IFN-alphaB2, IFN-alphaG, IFN-alphaI, IFN-beta1a, IL-10 RbetaFc Chimera

4 hours

Research Use Only

IL-29 is distantly related to type I interferons and the IL-10 family. Expression of IL-29 is induced by viral infection which interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor beta (IL10RB) and interleukin 28 receptor alpha . IL-29 exhibits common features with type I IFNs such as antiviral activity, antiproliferative activity and in vivo antitumour activity. IL-29 acts similarly to IFNs, but is less effective generally and has activity in a more limited range of cell lines. IL-29 produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and therefore is an important factor in activating innate immune responses at the site of viral infection. IFN-Lambda 1 antiviral and antiproliferative activity requires Interferon-Lambda 2 receptor tyrosine residues. Recombinant human IL-29 produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 181 amino acids and having a molecular mass of?20 kDa.

2°C to 8°C

41116133